CURRENT
ISSUE
1572
May 20, 2019
The FDA has approved Inbrija (Acorda), an orally
inhaled dry-powder formulation of levodopa, for
intermittent treatment of "off" episodes in patients
with Parkinson's disease (PD) being treated with
carbidopa/levodopa (Sinemet, and others).... Continue reading
More from Issue 1572
Previous Issue: 1571 May 6, 2019
- Insulins for Type 2 Diabetes
- Brexanolone (Zulresso) for Postpartum Depression
- Siponimod (Mayzent) - A New Drug for Multiple Sclerosis
- In Brief: Tegaserod (Zelnorm) Returns
- Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)
Coming Soon
Drugs for Psoriasis
Romosozumab (Evenity) for Postmenopausal Osteoporosis
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
Risankizumab (Skyrizi) - A New IL-23 Antagonist for Plaque Psoriasis
Tafenoquine for Malaria
Subscribe
Tweets
FROM
ISSUE
1572
The FDA has approved omadacycline (Nuzyra – Paratek),
a semisynthetic tetracycline derivative, for once-daily
IV and oral treatment of community-acquired bacterial
pneumonia (CAP) and acute bacterial skin and skin
structure infections (ABSSSIs) in adults. ... Continue reading
